An Integrative Approach for the Transplantation of High-Risk Sensitized Patients
- 27 September 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90 (6) , 645-653
Abstract
Background. Sensitized patients have a lower chance of receiving a crossmatch-negative kidney and, if transplanted, are at risk of antibody-mediated allograft rejection. Methods. For safe and timely transplantation of sensitized patients at our center, we developed an integrative algorithm that includes identification of high-risk patients, good human leukocyte antigen match, inclusion in the Eurotransplant Acceptable Mismatch Program when applicable, apheresis, anti-CD20 therapy, posttransplant antibody monitoring, and protocol biopsies. Thirty-four high-risk recipients of a deceased donor kidney (DDK: n=28) or living donor kidney (LDK: n=6) were transplanted using this algorithm. Results. One-year graft survival, death-censored graft survival, and patient survival rates in DDK recipients were 92.4%, 96.4%, and 95.8%, respectively. No graft loss or patient death was observed in the six LDK patients. Median serum creatinine at 1 year in DDK and LDK recipients was 1.2 and 1.4 mg/dL, respectively. Eleven DDK and three LDK patients experienced at least one biopsy-proven acute rejection episode, mostly showing borderline changes. Antibody-mediated rejection without graft loss was diagnosed in two DDK and one LDK patients. Delayed graft function was observed in 13 DDK and 1 LDK patients. Infectious complications were infrequent. Conclusions. We describe an algorithm for the categorization and treatment of presensitized high-risk patients. This protocol provides effective prevention of antibody-mediated rejection and is associated with a low rate of side effects and good graft outcome.Keywords
This publication has 37 references indexed in Scilit:
- Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: A Collaborative Transplant Study reportHuman Immunology, 2009
- Positive Cross-Match Living Donor Kidney Transplantation: Longer-Term OutcomesAmerican Journal of Transplantation, 2009
- Excellent Renal Allograft Survival in Donor-Specific Antibody Positive Transplant Patients—Role of Intravenous Immunoglobulin and Rabbit Antithymocyte GlobulinTransplantation, 2009
- Rituximab and Intravenous Immune Globulin for Desensitization during Renal TransplantationNew England Journal of Medicine, 2008
- B‐lymphocyte contributions to human autoimmune diseaseImmunological Reviews, 2008
- Pretransplant Donor-Specific Antibodies in Cytotoxic Negative Crossmatch Kidney Transplants: Are They Relevant?Transplantation, 2008
- The Regulatory/Cytotoxic Graft-Infiltrating T Cells Differentiate Renal Allograft Borderline Change From Acute RejectionTransplantation, 2007
- B cells: a rational target in alloantibody‐mediated solid organ transplantation rejectionClinical Transplantation, 2005
- Renal Transplantation of Highly Sensitised Patients via Prioritised Renal Allocation ProgramsNephron, 2002
- Early protocol renal allograft biopsies and graft outcomeKidney International, 1997